Analyst firms · Barclays · THC

Barclays THC price target and rating history

Tenet Healthcare Corporation (THC) · Health Care

Barclays rates Tenet Healthcare Corporation (THC) Overweight with a $113 price target, as of its latest action on Mar 6, 2024. It has published 5 rating actions on THC since August 2021, including 1 upgrade and 0 downgrades.

Current rating

Overweight

Price target

$113

Median target, all firms

Too few

Actions on THC

5

Barclays price target on THC

Every Barclays rating on THC

• Mar 6, 2024
  InitiateBarclays starts coverage at Overweight, price target $113
• Feb 9, 2022
  ReiterateBarclays raises its price target to $99 from $87, keeps Overweight
• Dec 21, 2021
  ReiterateBarclays raises its price target to $87 from $81, keeps Overweight
• Sep 8, 2021
  ReiterateBarclays raises its price target to $79 from $78, keeps Overweight
• Aug 12, 2021
  UpgradeBarclays upgrades to Overweight from Equal-Weight, price target $62 to $77

Questions about Barclays and THC

What is Barclays's price target for THC?

Barclays's latest stated price target for Tenet Healthcare Corporation (THC) is $113, from its action on Mar 6, 2024.

What is Barclays's rating on THC?

Barclays rates THC Overweight, a bullish rating, as of Mar 6, 2024.

When did Barclays last change its view on THC?

On Mar 6, 2024, Barclays starts coverage at Overweight, price target $113.

More THC rating histories

• Goldman Sachs3
• Wells Fargo3
• Mizuho3
• Credit Suisse3
• Leerink Partners4
• Citigroup3

All Barclays ratingsTHC news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.